Traduzione in corso

Early Clinical Development of ARQ 197, a Selective, Non–ATPCompetitive

Inhibitor Targeting MET Tyrosine Kinase for the

Treatment of Advanced Cancers

ALEX A. ADJEI, BRIAN SCHWARTZ, EDWARD GARMEY

doi: 10.1634/theoncologist.2010-0380

 

Parole chiave: c-MET • EGFR • Epithelial growth factor inhibitor • Kinase receptor inhibitor • Hepatocyte growth factor

Advertisements